Our study highlights the intricate interplay between insulin and IGF1 signaling in the hypothalamus and suggests that targeting IGF1 resistance may offer new therapeutic avenues for treating metabolic disorders associated with hyperinsulinemia. The gene discussed is IGF1; the disease is hyperinsulinism.